Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background The development and widespread use of an effective SARS-CoV-2 vaccine could help prevent substantial morbidity and mortality associated with COVID-19 infection and mitigate many of the secondary effects associated with non-pharmaceutical interventions. The limited availability of an effective and licensed vaccine will task policymakers around the world, including in India, with decisions regarding optimal vaccine allocation strategies. Using mathematical modelling we aimed to assess the impact of different age-specific COVID-19 vaccine allocation strategies within India on SARS CoV-2-related mortality and infection. Methods We used an age-structured, expanded SEIR model with social contact matrices to assess different age-specific vaccine allocation strategies in India. We used state-specific age structures and disease transmission coefficients estimated from confirmed Indian incident cases of COVID-19 between 28 January and 31 August 2020. Simulations were used to investigate the relative reduction in mortality and morbidity of vaccinate allocation strategies based on prioritizing different age groups, and the interactions of these strategies with several concurrent non-pharmacologic interventions (i.e., social distancing, mandated masks, lockdowns). Given the uncertainty associated with current COVID-19 vaccine development, we also varied several vaccine characteristics (i.e., efficacy, type of immunity conferred, and rollout speed) in the modelling simulations. Results In nearly all scenarios, prioritizing COVID-19 vaccine allocation for older populations (i.e., >60yrs old) led to the greatest relative reduction in deaths, regardless of vaccine efficacy, control measures, rollout speed, or immunity dynamics. However, preferential vaccination of this target group often produced higher total symptomatic infection counts and more pronounced estimates of peak incidence than strategies which targeted younger adults (i.e., 20-40yrs or 40-60yrs) or the general population irrespective of age. Vaccine efficacy, immunity type, target coverage and rollout speed all significantly influenced overall strategy effectiveness, with the time taken to reach target coverage significantly affecting the relative mortality benefit comparative to no vaccination. Conclusions Our findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Including younger adults in the prioritisation group can reduce overall infection rates, although this benefit was countered by the larger mortality rates in older populations. Ultimately an optimal vaccine allocation strategy will depend on vaccine characteristics, strength of concurrent non-pharmaceutical interventions, and region-specific goals such as reducing mortality, morbidity, or peak incidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2
Sanche, S., Lin, Y. T., Xu, C., Romero-Severson, E., Hengartner, N., & Ke, R. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200282 · Cited by 1,619
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195 · cited 1×
“However, COVID-19 vaccine challenge studies in primates demonstrated reductions in symptomatic disease and viral load, but did not produce sterilising immunity (Corbett et al., 2020; van Doremalen et al., 2020).”
BackgroundEvaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · cited 1×
“However, COVID-19 vaccine challenge studies in primates demonstrated reductions in symptomatic disease and viral load, but did not produce sterilising immunity (Corbett et al., 2020; van Doremalen et al., 2020).”
Walker, P. G. T., Whittaker, C., Watson, O. J., Baguelin, M., Winskill, P., Hamlet, A., Djafaara, B. A., Cucunubá, Z., Olivera Mesa, D., Green, W., et al. (2020) · Science · doi:10.1126/science.abc0035 · Cited by 993
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · cited 1×
“However, COVID-19 vaccine challenge studies in primates demonstrated reductions in symptomatic disease and viral load, but did not produce sterilising immunity (Corbett et al., 2020; van Doremalen et al., 2020).”
BackgroundRapid COVID-19 vaccine development
Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771 · cited 1×
“An unprecedented ffort is currently underway to rapidly develop effective COVID-19 accines, with several stakeholders working together to condense he process into months (Graham, 2020).”
Epidemiology and transmission dynamics of COVID-19 in two Indian states
Laxminarayan, R., Wahl, B., Dudala, S. R., Gopal, K., Mohan B, C., Neelima, S., Jawahar Reddy, K. S., Radhakrishnan, J., & Lewnard, J. A. (2020) · Science · doi:10.1126/science.abd7672 · Cited by 485 · cited 2×
“…period) 16.4 days Bi et al. (2020) 1/m (immunity duration) 1 year Estimated (other values in supplemental material) p (proportion of symptomatic infections) Age-specific Davies et al. (2020) D (case fatality rate) Age-specific Laxminarayan et al. (2020) oderate lockdown, or strong lockdown).”
InfluentialSelf-citation
Metadata
- Authors
- Foy, B. H., Wahl, B., Mehta, K., Shet, A., Menon, G. I., & Britto, C.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 103
- Pages
- 431-438
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3113666824
- Cited by
- 247
- References
- 13
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. https://app.cochat.ai/papers/10.1016/j.ijid.2020.12.075
- The paper
- Foy, B. H., Wahl, B., Mehta, K., Shet, A., Menon, G. I., & Britto, C. (2021). Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2020.12.075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.